Wall Street analysts expect that Glaukos Corp (NYSE:GKOS) will report sales of $56.18 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Glaukos’ earnings, with the lowest sales estimate coming in at $54.81 million and the highest estimate coming in at $58.10 million. Glaukos reported sales of $43.16 million during the same quarter last year, which indicates a positive year over year growth rate of 30.2%. The firm is scheduled to issue its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Glaukos will report full-year sales of $229.03 million for the current fiscal year, with estimates ranging from $224.50 million to $236.10 million. For the next fiscal year, analysts anticipate that the business will report sales of $271.04 million, with estimates ranging from $263.40 million to $279.93 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Glaukos.
Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. Glaukos had a negative net margin of 5.93% and a negative return on equity of 6.90%. The company had revenue of $54.03 million during the quarter, compared to the consensus estimate of $50.13 million.
In related news, CFO Joseph E. Gilliam sold 2,603 shares of Glaukos stock in a transaction on Monday, May 13th. The shares were sold at an average price of $65.14, for a total value of $169,559.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 17,500 shares of company stock worth $1,251,929. 8.70% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. purchased a new position in shares of Glaukos in the first quarter valued at about $48,000. Marshall Wace North America L.P. purchased a new position in shares of Glaukos during the first quarter valued at about $55,000. NumerixS Investment Technologies Inc increased its position in shares of Glaukos by 20.7% during the fourth quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock valued at $61,000 after buying an additional 189 shares during the period. Oppenheimer Asset Management Inc. increased its position in shares of Glaukos by 251.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 1,938 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,387 shares during the period. Finally, First Republic Investment Management Inc. purchased a new position in shares of Glaukos during the first quarter valued at about $244,000. Hedge funds and other institutional investors own 95.78% of the company’s stock.
NYSE GKOS opened at $75.40 on Friday. Glaukos has a 52-week low of $36.89 and a 52-week high of $83.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.72 and a quick ratio of 6.23. The company has a market cap of $2.76 billion, a P/E ratio of -203.78 and a beta of 1.57. The stock’s fifty day moving average is $69.77.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.